Core Viewpoint - The controlling shareholder of Huason Pharmaceutical plans to reduce its stake again, indicating potential liquidity needs despite the company's stable fundamentals [1][3]. Group 1: Shareholder Reduction Plans - Chengdu Dijiang, the controlling shareholder, intends to reduce its holdings by up to 12.52 million shares, representing 3% of the total share capital, within three months from the announcement date [1]. - Executive Peng Xiaoyan also plans to sell up to 4,375 shares, which is 0.0010% of the total share capital [1]. - This marks the second reduction by the controlling shareholder within a year, with a previous reduction of the same amount completed between November 2024 and February 2025, resulting in proceeds of 14.7 million yuan [2]. Group 2: Company Performance - Huason Pharmaceutical reported a revenue of 775 million yuan in 2024, a year-on-year increase of 12.04%, and a net profit of 76.73 million yuan, up 134.66% [3]. - The growth is attributed to strong performance in traditional Chinese medicine products, with five exclusive Chinese patent medicines seeing a revenue increase of 21.71% [3]. - In Q1 2025, the company achieved a revenue of 239 million yuan, a 4.62% year-on-year growth, with net profits slightly increasing by 0.0098% [3][4]. Group 3: Market Dynamics - The revenue growth in Q1 2025 was slower due to a decrease in market demand compared to the previous year when flu cases were high, leading to increased sales of key products [4]. - Sales of the key product, Ganqi Bingmei Tablets, experienced a decline in revenue compared to the previous year, while other products like Liwei Anshen Capsules and Tongxie Ning Granules saw significant growth of 32.10% and 80.24%, respectively [4].

Core Viewpoint - The announcement details the share reduction plan by the controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and senior management personnel, indicating their intention to sell a total of up to 12,527,889 shares, which is approximately 3% of the company's total share capital, over a specified period [1][3][9] Shareholder Information - Chengdu Local Construction Machinery Engineering Co., Ltd. holds 175,572,175 shares, accounting for 42.04% of the company's total share capital [1] - Senior management personnel, specifically Ms. Peng Xiaoyan, holds 17,500 shares, representing 0.0042% of the total share capital [1] Share Reduction Plan Details - Chengdu Local Construction plans to reduce its holdings by up to 4,175,963 shares (1% of total shares) through centralized bidding and up to 8,351,926 shares (2% of total shares) through block trading, totaling a maximum of 12,527,889 shares [1][3] - Ms. Peng Xiaoyan intends to reduce her holdings by no more than 4,375 shares, which is less than 0.01% of the total share capital [2][3] Reduction Timing and Method - The reduction period is set from June 6, 2025, to September 5, 2025, starting 15 trading days after the announcement [1][3] - The reduction will be executed through centralized bidding and block trading, with the price determined by market conditions [2][5] Compliance and Commitments - Chengdu Local Construction has committed to adhere to relevant regulations regarding share reduction and has previously complied with lock-up commitments [6][7][8] - Ms. Peng Xiaoyan has also followed the regulations regarding share transfer during her tenure and after leaving the company [8] Risk and Impact Assessment - The company emphasizes that the share reduction plan will not lead to a change in control or significantly impact the company's governance structure or ongoing operations [9]

证券代码：002907 证券简称：华森制药 公告编号：2025-039 重庆华森制药股份有限公司 关于公司控股股东及高级管理人员减持股份预披露 的公告 | 股东名称 | 持股数量（股） | 占公司总股本比例（%） | | --- | --- | --- | | 成都地建 | 175,572,175 | 42.0435 | | 彭晓燕 | 17,500 | 0.0042 | 二、本次股份减持计划的主要内容 （一）成都地建 、 减持股份数量 ： 拟减持公司股份数量不超过12,527,889股（含）（若此期间 （二）彭晓燕 公司控股股东成都地方建筑机械化工程有限公司、高级管理人员彭 晓燕女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 重庆华森制药股份有限公司（以下简称"公司"）于近日收到公司控股股东成 都地方建筑机械化工程有限公司（以下简称"成都地建"）和高级管理人员彭晓燕 女士发来的《关于计划减持公司股份的告知函》。 持有公司175,572,175股份的控股股东成都地建计划自本公告披露之日起1 ...

华森制药（002907）公告，控股股东成都地建计划减持不超过1252.79万股，即不超过公司总股本的 3%。高管彭晓燕计划减持不超过4375股，即不超过公司总股本的0.0010%。 ...

Group 1: Company Performance and Market Expansion - In Q1 2025, the company achieved revenue of 239 million CNY, a 4.62% increase year-on-year, with a slowdown attributed to reduced market demand for key products [4] - The five key traditional Chinese medicine products saw a slight revenue growth of 0.93% in Q1 2025, with notable increases in sales for specific products: Six Flavor Anshen Capsules grew by 32.10% and Tongxie Ning Granules by 80.24% [4][13] - The company has successfully registered key products in overseas markets, including the approval of three traditional Chinese medicine products in Singapore, marking a significant milestone for international sales [3] Group 2: Research and Development Initiatives - The company is advancing four innovative drug research pipelines targeting various cancers, with 17 patent applications filed as of the end of 2024 [8][9] - The first global innovative drug project, HSN003, has shown promising efficacy data and is expected to complete IND application by 2025 [8] - The company has established a "333" pipeline strategy to enhance R&D capabilities and ensure a steady flow of new products [14][15] Group 3: Response to Market Challenges - The company is adapting to the impact of centralized drug procurement, focusing on multi-channel development and maintaining a strong presence in public hospitals, which account for approximately 70% of sales [10][12] - Strategies include exploring diverse product lines, such as special medical foods, to mitigate risks associated with price reductions in existing markets [6][5] - The company emphasizes continuous innovation and market expansion to counteract the effects of centralized procurement [6][14] Group 4: Future Outlook and Growth Strategies - The company plans to enhance its digital marketing efforts through various online platforms to boost product visibility and sales [5] - Long-term growth is expected from the continuous launch of new products, with a focus on both generic and traditional Chinese medicine development [14][15] - The company aims to strengthen its market position by expanding into non-public hospital channels and leveraging e-commerce platforms [13]

Financial Performance - In 2024, the company achieved operating revenue of 774 million yuan, a year-on-year increase of 12.04% [1] - The net profit attributable to shareholders reached 76.73 million yuan, a significant year-on-year growth of 134.66% [1] - The net profit after deducting non-recurring gains and losses was 51.21 million yuan, up 146.94% year-on-year [1] - Basic earnings per share were 0.18 yuan [1] Profitability Metrics - The gross profit margin for 2024 was 57.27%, an increase of 2.30 percentage points year-on-year [3] - The net profit margin improved to 9.90%, up 5.17 percentage points year-on-year [3] - The weighted average return on net assets was 4.68%, an increase of 2.65 percentage points year-on-year [3] Expense and Cash Flow Analysis - Total period expenses for 2024 amounted to 357 million yuan, a year-on-year increase of 7.03% [3] - Selling expenses were 251 million yuan, up 18.88% year-on-year due to increased academic promotion activities [3] - Research and development expenses decreased by 24.31% to 59.13 million yuan [3] - Net cash flow from operating activities was 162 million yuan, down 26.25% year-on-year [3] - Net cash outflow from investing activities was 107 million yuan, primarily for production base construction and smart transformation [3] Business Segment Performance - Revenue from the pharmaceutical industry was 651 million yuan, a year-on-year increase of 15.39%, accounting for 84.02% of total revenue [3] - Revenue from ear, nose, and throat medications was 265 million yuan, up 28.26% year-on-year [3] - Revenue from digestive system medications reached 178 million yuan, a year-on-year increase of 11.46% [3] - Revenue from psychiatric and neurological medications was 145 million yuan, up 14.06% year-on-year [3] New Business Developments - The company received approval for the special medical food project TY005, with production lines gradually releasing capacity [4] - E-commerce sales exceeded 13 million yuan [4] - The company is advancing four tumor-related Class 1 new drug pipelines, with the HSN003 project entering the IND application preparation stage [4] - A cash dividend of 0.50 yuan per 10 shares (including tax) is proposed for 2024 [4]

关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：002907 证券简称：华森制药 公告编号：2025-038 重庆华森制药股份有限公司 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝20150018），本次变更主要涉 及增加生产范围（仅限注册申报使用）。具体情况如下： 一、变更内容 1.增加生产范围（仅限于注册申报）：重庆市荣昌区昌州街道板桥路 143 号增 加生产范围（仅限于注册申报）：硬胶囊剂（含抗肿瘤类）（克唑替尼胶囊）。 克唑替尼胶囊自 2013 年在中国市场推出，2018 年已被纳入医保，并累积超过 十年的临床应用经验。该药物在临床上主要用于治疗间变性淋巴瘤激酶（ALK）阳 性的局部晚期或转移性非小细胞肺癌（NSCLC）患者，以及 ROS1 阳性的晚期非小细 胞肺癌（NSCLC）患者。作为一线治疗方案，克唑替尼胶囊为 ALK/ROS1 阳性晚期非 小细胞肺癌患者提供了超过七年的总生存期益处。作为小分子靶向抗肿瘤治疗药物， 克唑替尼胶囊是全 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-037 重庆华森制药股份有限公司 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 3 个药品的《药品再注 册批准通知书》。现将相关情况公告如下： （二）头孢氨苄胶囊 药品通用 名 称：头孢氨苄胶囊 英文名 / 拉 丁 名：Cefalexin Capsules 受 理 号：CYHZ2414672 渝 通 知 书 编 号：2025R037109 剂 型：胶囊剂 规 格：0.25g(按 C16H17N3O4S 计) 注册分类：化学药品 药 品 注 册 标 准 编 号：《中国药典》2020 年版二部 药 品 批 准 文 号：国药准字 H50021280 药 品 有 效 期：24 个月 药 品 批 准 文 号 有 效 期：至 2030 年 04 月 28 日 审批结论：经审查，同意本品再注册。由于本品长期未生产， 恢复生产前，持有人应按相关文件要求完 ...

Core Viewpoint - The company, Watson Pharmaceuticals, has received approval from the Chongqing Drug Administration for the re-registration of three pharmaceutical products, indicating a positive regulatory development for the company [1] Group 1: Product Approvals - The approved products include Oyster Calcium Carbonate Granules, Cefalexin Capsules, and Lincomycin Hydrochloride Capsules [1] - The approval for Oyster Calcium Carbonate Granules is valid until May 9, 2030 [1] - The approval for Cefalexin Capsules is valid until April 28, 2030 [1] - The approval for Lincomycin Hydrochloride Capsules is valid until May 9, 2030 [1]

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 239 million CNY, a year-on-year increase of 4.62%, with a slight growth of 0.93% in five key traditional Chinese medicine products [2] - The sales revenue of the key product Ganji Bingmei Tablets declined due to reduced market demand, contrasting with a significant increase in sales during the same period last year [2] - The net cash flow from operating activities in 2024 was 162 million CNY, accounting for 210.83% of net profit, despite a 26.25% decrease compared to the previous year [11] Group 2: Market Expansion and Product Development - The company has made significant strides in overseas market expansion, with FDA approvals for multiple products and production facilities [4] - The company’s traditional Chinese medicine products have received registration approvals in Singapore, marking a key milestone for international market entry [4] - The company is actively developing special medical foods, with a global market size of approximately 3 billion USD and a domestic market size of about 7 billion CNY [8] Group 3: Research and Development - The company is advancing four innovative drug research pipelines targeting various cancers, with 17 patent applications filed by the end of 2024 [6] - The company has established a "333" pipeline structure to enhance its product offerings and market competitiveness [3] - The first global innovative drug project is expected to complete IND application by 2025, showcasing the company's commitment to innovation [7] Group 4: Strategic Response to Market Challenges - The company is exploring diversified development strategies in response to price reductions from centralized procurement, focusing on new product launches and market expansion [5] - The company aims to increase market share in public hospitals while expanding into private hospitals, retail pharmacies, and e-commerce platforms [9] - The company plans to implement a stock incentive plan to align management interests with company growth [13]